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Abstract Hypoxia-inducible factor-1K (HIF-1K) plays a cen-
tral role in oxygen homeostasis. In normoxia, HIF-1K is a short
lived protein, whereas hypoxia rapidly increases HIF-1K protein
levels by relaxing its ubiquitin^proteasome-dependent degrada-
tion. In this study, we show that the p42/p44 MAP kinase
cascade, known to phosphorylate HIF-1K, does not modulate the
degradation/stabilization profile of HIF-1K. However, we pre-
sent evidence that the rate of HIF-1K degradation depends on
the duration of hypoxic stress. We demonstrate that degradation
of HIF-1K is suppressed by: (i) inhibiting general transcription
with actinomycin D or (ii) specifically blocking HIF-1-dependent
transcriptional activity. In keeping with these findings, we
postulate that HIF-1K is targetted to the proteasome via a
HIF-1K proteasome targetting factor (HPTF) which expres-
sion is directly under the control of HIF-1-mediated transcrip-
tional activity. Although HPTF is not yet molecularly identified,
it is clearly distinct from the von Hippel^Lindau protein
(pVHL). ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric tran-
scription factor composed of the HIF-1K (120 kDa) and HIF-
1L subunits (94 kDa) [1]. Both HIF-1 subunits belong to the
subfamily of basic-helix-loop-helix transcription factors con-
taining a PAS (PER-ARNT-SIM) motif [2]. HIF-1L is the
already characterized aryl hydrocarbon nuclear translocator
(ARNT) previously shown to heterodimerize with the aryl
hydrocarbon receptor, whereas the HIF-1K subunit is speci¢c
for the hypoxic responses [3]. Recently, in addition to HIF-1K
and HIF-1L, cloning experiments have identi¢ed several new
members of the HIF family of transcription factors [4]. HIF-1
plays a central role in oxygen homeostasis by inducing the
expression of a broad range of genes in a hypoxic-dependent
manner: erythropoietin (EPO), vascular endothelial growth
factor (VEGF), VEGFR-1, glucose transporter-1 (GLUT-1),
inducible nitric oxide synthase (i-NOS), heme oxygenase (HO-
1), transferrin, tyrosine hydroxylase, and almost every gene in
the glycolytic pathway [5,6]. All these genes contain at least
one hypoxia response element that speci¢es the binding of
HIF-1.
Several studies have demonstrated that the hypoxic activa-
tion of HIF-1 is a multistage and a complex process. How-
ever, hypoxia-mediated induction of HIF-1K appears to be the
primary mode of regulation since the expression of the rate
limiting K subunit determines the activity of the HIF-1 com-
plex [7,8]. HIF-1K is a short lived protein that is maintained at
low and often undetectable levels in normoxia, whereas it is
strongly induced in hypoxic cells [2,7]. Indeed, as quickly as
HIF-1K is induced, it is even more rapidly degraded upon
return to normoxic conditions [2,7]. Previous results have
shown that, in oxygenated cells, HIF-1K is quickly ubiquiti-
nated and degraded by the proteasome system, whereas hyp-
oxia induces HIF-1K by relaxing its ubiquitin^proteasome-
mediated degradation [8^10]. Hence, regulation of the protea-
some-dependent degradation of HIF-1K appears to be a piv-
otal step in the hypoxic induction of HIF-1.
In spite of extensive studies on the molecular mechanisms
underlying the proteasome-dependent degradation of HIF-1K,
it is only recently that a major breakthrough has been done.
The product of the von Hippel^Lindau tumor suppressor gene
(pVHL) has been demonstrated to interact directly with HIF-
1K as a component of an E3 ubiquitin^protein ligase complex
responsible for the degradation of HIF-1K [11^14]. However,
the association of pVHL and HIF-1K has been reported to be
constitutive and independent of oxygen levels. Indeed, the
signaling components regulating the ‘switch’ to proteasomal
degradation in normoxic conditions are not still fully charac-
terized. In this work, we show that p42/p44 MAP kinases,
known to phosphorylate HIF-1K, are not implicated in the
stabilization of HIF-1K protein or the regulation of its ubiq-
uitin^proteasome-dependent degradation. We present evi-
dence that HIF-1K degradation depends on HIF-1-mediated
transcriptional activity. We propose a model in which a HIF-
1K proteasome targetting factor, referred to here as HPTF, is
involved in this process. We demonstrate that HPTF is dis-
tinct from the previously characterized pVHL, and we pro-
pose that a hypoxia-regulated gene encodes HPTF. This
working model provides an autoregulatory feedback mecha-
nism for HIF-1K degradation.
2. Materials and methods
2.1. Material and plasmid construction
The transcriptional inhibitor, actinomycin D, was from Boehringer
Mannheim. PD 98059 was from New England Biolabs. Estradiol and
monoclonal anti-phospho-p42/p44 MAP kinases antibody were from
Sigma. The anti-HIF-1K antibody (antiserum 2087) was raised in our
laboratory in rabbits immunized against the last 20 amino acids C-
terminal of the human HIF-1K. Monoclonal antibody against pVHl
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was from Pharmingen (Ig32). The HIF-1K expression vector
pcDNA3-HA-DN-HIF-1K has previously been described [15].
2.2. Cell culture and transfections
HeLa cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 7.5% inactivated fetal calf serum (FCS),
penicillin G (50 U/ml), and streptomycin (50 Wg/ml) (Gibco-BRL) in a
CO2 incubator (5% CO2) at 37‡C. CCL39-Raf-1:ER cells were cul-
tured in the same media but in the absence of phenol red in order to
reduce the basal activity of the chimera. Cells were arrested by total
serum deprivation for 24 h. Hypoxic conditions were performed by
incubation of cells in a sealed ‘Bug-Box’ anaerobic workstation (Rus-
kinn Technologies, Jouan, France). The oxygen in this workstation
was maintained at 1^2% with residual gas mixture being 93^94%
nitrogen, and 5% carbon dioxide.
Subcon£uent HeLa cells on 60 mm culture dishes were transfected
with 10 Wg of either pcDNA3 or pcDNA3-HA-DN-HIF-1K by the
calcium phosphate method. After 16 h, plasmid DNA was removed
and cells were incubated in DMEM medium containing 7.5% FCS. At
48 h post-transfection, cells were incubated under normoxia (20% O2)
or hypoxia (1^2% O2) for 3 h after which hypoxic cells were returned
to 20% O2 for di¡erent times. Under these conditions and using GFP
as a co-marker, we usually transfected about 70^80% of cells.
2.3. Immunoprecipitation and immunoblot analysis
In order to analyze HIF-1K expression, cellular proteins were ex-
tracted with Triton X-100 lysis bu¡er (0.1% Triton X-100, 50 mM
Tris^HCl (pH 7.5), 100 mM NaCl, 5 mM EDTA, 50 mM sodium
£uoride, 40 mM L-glycerophosphate, 200 WM sodium orthovanadate,
5 Wg/ml aprotinin, 0.7 Wg/ml pepstatin, 0.5 Wg/ml leupeptin, and
0.1 mM phenylmethylsulfonyl £uoride) and total cellular extracts
(50 Wg) were resolved in sodium dodecyl sulfate (SDS)^polyacryl-
amide (7.5%) gels. For the pVHL protein, proteins from HeLa cells
were extracted by using the previously described lysis bu¡er with
addition of 0.5% sodium deoxycholate. Clari¢ed lysates (500 Wg)
were incubated for 2 h with the anti-HIF-1K antiserum (5 Wl). Immu-
nocomplexes were collected on protein A Sepharose (Pharmacia),
washed three times with the lysis bu¡er, boiled in Laemmli loading
bu¡er, and separated by SDS^PAGE (12%). Afterwards, proteins
were electrophoretically transferred onto a PVDF membrane (Immo-
bilon-P, Millipore) and revealed with the speci¢c antibodies as indi-
cated. The bands were visualized with the ECL system (Amersham
Pharmacia Biotech).
3. Results
3.1. p42/p44 MAP kinase activity does not a¡ect the
stabilization/degradation pattern of HIF-1K
Phosphorylation and dephosphorylation activities have
often been implicated in the stabilization and/or degradation
of a number of transcription factors, and other proteins regu-
lated by the proteasome system [16]. Interestingly, results
from our laboratory have demonstrated that HIF-1K is a
phosphoprotein that is speci¢cally phosphorylated by p42/
p44 MAP kinases in vitro and in vivo [17]. In order to specif-
ically evaluate whether p42/p44 MAP kinase activity a¡ects
ubiquitin^proteasome-mediated degradation of HIF-1K, we
used a derivative of the CCL39 cell line stably expressing
the Raf-1:ER chimera. This protein is a fusion between the
catalytic domain of Raf-1, the MAPKKK upstream activator
of the p42/p44 MAP kinase pathway, and the ligand binding
domain of the estradiol receptor. Addition of estradiol to
these arrested cells induces a rapid and strong stimulation
of p42/p44 MAP kinases that persists as long as estradiol is
present in the medium [18^20]. Therefore, CCL39-Raf-1:ER
starved cells were incubated either in normoxic (20% O2) or
hypoxic (1^2% O2) conditions as indicated in the legend in the
presence of either estradiol or the MEK inhibitor, PD 98059,
for the last 30 min. HIF-1K protein levels were determined by
immunoblot analysis of total cell extracts. Results from Fig.
1A showed that HIF-1K is strongly and rapidly induced by
hypoxia either in PD 98059-treated or estradiol-stimulated
cells. Of note the marked di¡erences in the migration pattern
of HIF-1K corresponding to varying levels of phosphoryla-
tion. As we have previously demonstrated, HIF-1K migrates
as a single band in quiescent cells, whereas the activation of
the p42/p44 MAP kinase pathway induces the phosphoryla-
tion and the ‘shift-up’ of HIF-1K (Fig. 1). We next evaluated
the pro¢le of HIF-1K degradation upon reoxygenation in the
same experimental conditions. As shown in Fig. 1B, this pro-
¢le remained very similar in control or estradiol-stimulated
cells. Interestingly, the rate of degradation seems to be iden-
tical for the hypophosphorylated and upper form of HIF-1K
(Fig. 1B, right panel). These results demonstrate that p42/p44
MAP kinase cascade, in CCL39 cells, does not signi¢cantly
modulate the stabilization/degradation kinetics of HIF-1K.
3.2. Degradation of HIF-1K depends on the duration of hypoxic
stress
HIF-1K is highly up-regulated by hypoxia in almost every
cell type tested. Interestingly, in HeLa cells as compared to
the CCL39 cell line, induced HIF-1K migrates with a pattern
showing the di¡erent phosphorylated forms of the protein
[17]. Therefore, for the rest of the study we used HeLa cells
as our cellular model. Thus, HeLa cells were incubated under
hypoxia for 1 h or 8 h after which they were returned to an
oxygenated atmosphere for periods of time varying between 0
and 30 min. As previously demonstrated, results from Fig. 2A
Fig. 1. p42/p44 MAP kinase activation does not a¡ect the expres-
sion patterns of HIF-1K. (A) CCL39-Raf-1:ER cells were starved
for 24 h, and then incubated under normoxia (20% O2 ; N) or hyp-
oxia (1^2% O2 ; H) for di¡erent times. Before the end of each treat-
ment (30 min), cells were stimulated with either 50 WM PD 98059
or 100 nM estradiol. (B) Starved CCL39-Raf-1:ER cells were incu-
bated under normoxia (20% O2 ; N) or hypoxia (1^2% O2 ; H) for
3 h after which hypoxic cells were returned to 20% O2 for 0^30
min. 30 min before the end of the hypoxic stress, Raf-1:ER cells
were stimulated with either 50 WM PD 98059 or 100 nM estradiol.
Total cell lysates were analyzed by immunoblotting with the anti-
bodies to HIF-1K and anti-phospho-p42/p44 MAP kinase. Essen-
tially identical results were obtained in three independent experi-
ments.
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showed that HIF-1K is strongly induced by hypoxia and rap-
idly degraded upon reoxygenation of hypoxic cells. However
and more interestingly, these results revealed that the rate of
HIF-1K degradation depends on the duration of hypoxic
stress. The increase of the hypoxic treatment from 1 h to 8 h
reduced the half-life of HIF-1K by 5-fold. Cells which under-
went the shortest hypoxic stress (1 h) had the longest HIF-1K
half-life (19 min), whereas the t1=2 of HIF-1K drastically fell to
5 min in cells that were maintained in hypoxia for 8 h (Fig.
2B). Indeed, cells stressed for 3 h showed an intermediate t1=2
(data not shown). As a control, the same cellular lysates were
analyzed by Western blot with an antibody against p42 MAP
kinase. The protein levels of this kinase, which is not a¡ected
by O2 tension, remained unmodi¢ed (data not shown). These
¢ndings suggest that the degradation of HIF-1K is dependent
on hypoxia-induced transcription and/or translation.
3.3. Actinomycin D inhibits HIF-1K degradation
We wanted to evaluate whether transcriptional or transla-
tional activities were implicated in the regulation of HIF-1K
breakdown. Unfortunately, since HIF-1K induction involves
on-going protein synthesis, the use of cycloheximide was ruled
out. To test whether oxygen-mediated HIF-1K degradation
depends on a hypoxia-induced transcriptional activity, HeLa
cells were incubated in 1^2% O2 for 8 h, either in the absence
or in the presence of actinomycin D, and then reoxygenated
for the indicated periods of time. In agreement with previous
studies showing that the HIF-1K mRNA is constitutively ex-
pressed and is not signi¢cantly a¡ected by hypoxia, results
from Fig. 3A demonstrated that inhibition of transcription
did not a¡ect the induction of HIF-1K protein upon hypoxic
stress. The addition of actinomycin D, however, had a signi¢-
cant inhibitory e¡ect on HIF-1K degradation upon reoxygen-
ation, whereas the p42 MAP kinase protein levels remained
una¡ected. The same result was obtained when the experiment
was performed in the presence of another transcriptional in-
hibitor, 5,6-dichlorobenzimidazole riboside (data not shown).
These ¢ndings suggest that hypoxia induces the transcription
of a gene(s) encoding a regulatory protein(s), which controls
the oxygen-mediated degradation of HIF-1K.
3.4. HIF-1-dependent transcriptional activity is required for
HIF-1K degradation
As we mentioned in Section 1, HIF-1 is a key mediator of
the hypoxic induction of many hypoxia-regulated genes. We
therefore wanted to evaluate the possibility that HIF-1-depen-
dent transcriptional activation controls oxygen-mediated HIF-
1K degradation. If we are right, the inhibition of the transcrip-
tional activity of HIF-1 should be able to slow down HIF-1K
degradation. Hence, we transfected HeLa cells with a domi-
nant negative mutant of HIF-1K. This mutant (pcDNA3-HA-
DN-HIF-1K) was obtained by a carboxyl-terminal truncation
of HIF-1K that eliminates the transactivating domains (amino
acids 390^826). Accordingly, the expression of this construct
has been shown to inhibit induction of reporter genes by
endogenous HIF-1 in a dose-dependent manner (Gothie¤, E.
and Pouysse¤gur, J., unpublished data). At 48 h post-transfec-
tion, cells were incubated either in normoxia or hypoxia for
3 h after which hypoxic cells were returned to 20% O2 for 0,
15 or 30 min. Total cell extracts were prepared, and HIF-1K
Fig. 2. HIF-1K half-life is inversely proportional to the duration of
hypoxic stress. HeLa cells were incubated under normoxia (20% O2 ;
N) or hypoxia (1^2% O2 ; H) for 1 h (8) or 8 h (E) after which
hypoxic cells were returned to 20% O2 for 0^30 min. Total cell
lysates were immunoblotted with anti-HIF-1K (A). The intensity of
HIF-1K signals in A was quanti¢ed and plotted (B). Essentially
identical results were obtained in three independent experiments per-
formed in duplicate.
Fig. 3. HIF-1-dependent transcriptional activity controls oxygen-
mediated degradation of HIF-1K. (A) HeLa cells, either untreated
or treated with 5 Wg/ml of actinomycin D for 30 min, were incu-
bated under normoxia (20% O2 ; N) or hypoxia (1^2% O2 ; H) for
8 h after which hypoxic cells were returned to 20% O2 for 0^30
min. Total cell lysates were immunoblotted with anti-HIF-1K (B).
Subcon£uent HeLa cells were transfected with 10 Wg of either empty
vector or HA-DN-HIF-1K expression vector. At 48 h post-transfec-
tion, cells were incubated under normoxia (20% O2 ; N) or hypoxia
(1^2% O2 ; H) for 3 h after which hypoxic cells were returned to
20% O2 for 0, 15, or 30 min. Total cell lysates were analyzed by im-
munoblotting with the antibody to HIF-1K. Results are representa-
tive of three independent experiments.
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protein levels analyzed by immunoblotting. Interestingly, re-
sults from Fig. 3B demonstrated that the ability of oxygen to
induce HIF-1K degradation was strongly inhibited by expres-
sion of the HIF-1K dominant negative mutant. Of note, HIF-
1K construct was expressed at similar levels (data not shown).
Taken together, these results clearly show that during hypox-
ia, HIF-1 is critically involved in the induction of a regulatory
protein(s), which is necessary for oxygen-mediated HIF-1K
degradation.
3.5. VHL is not a hypoxia-inducible gene
Ratcli¡e’s group has nicely demonstrated that the product
of the von Hippel^Lindau tumor suppressor gene (pVHL)
plays an essential role on HIF-1K degradation [11]. In addi-
tion, our above results lead to the notion that hypoxia via
HIF-1 controls the expression of a factor(s) which is critical
for the oxygen-induced degradation of HIF-1K. Is pVHL this
hypoxia-inducible regulatory protein? To answer this ques-
tion, cellular lysates from HeLa cells incubated for di¡erent
periods in normoxia or hypoxia were analyzed by immunoblot
using an antibody against pVHL. This antibody detects a
single protein migrating in a 12% SDS^polyacrylamide gel
as a band which corresponds to a molecular mass of 24 kDa.
This band has been validated as pVHL by a coimmunoprecip-
itation assay using the anti-HIF-1K speci¢c antibodies (Fig. 4,
right panel). Results from Fig. 4 (left panel) clearly demon-
strated that the expression level of pVHL in whole cellular
extracts is not a¡ected even after 8 h of incubation in 1^2%
O2, whereas the same hypoxic treatment was found to dras-
tically accelerate the rate of HIF-1K degradation (Fig. 2A). In
addition, we showed that the interaction between HIF-1K and
pVHL, by immunoprecipitation assays, was not modi¢ed by
the length of the hypoxic stress (data not shown). Hence, we
conclude that pVHL is distinct from the regulatory protein,
actinomycin D-sensitive and HIF-1-dependent, which would
be implicated in the regulatory mechanism here presented.
4. Discussion
HIF-1 plays an essential role in embryonic development,
cellular and systemic physiology [5,6]. HIF-1 activity is crit-
ically dependent on the expression of HIF-1K [7,8], which
protein levels are tightly regulated by oxygen concentrations
via the ubiquitin^proteasome system [11^14]. In this work, we
Fig. 4. Hypoxia does not modulate the expression of the von Hip-
pel^Lindau protein (pVHL). HeLa cells were incubated under nor-
moxia (20% O2 ; N) or hypoxia (1^2% O2 ; H) for 4 h or 8 h. Total
cell lysates were immunoblotted with anti-HIF-1K or anti-pVHL
antibodies (left panel). The same cellular extracts (N and H (8 h))
were immunoprecipitated using the anti-HIF-1K antibody. These im-
munoprecipitates were analyzed by SDS^PAGE and immunoblotted
with the antibody to HIF-1K or pVHL (right panel). Essentially
identical results were obtained in three independent experiments.
Fig. 5. Working model depicting a potential mechanism by which HIFK degradation can be regulated. During hypoxia, HIFK is induced and
HIF-1-dependent transcriptional activation leads to the expression of HPTF. Upon normoxia, HPTF associates with the HIFK/pVHL complex
and targets HIF-1K to the proteasome. HIF-2K should also be subjected to a similar regulatory mechanism.
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focused our attention on the characterization of the mecha-
nisms controlling proteasome-mediated degradation of HIF-
1K.
The ubiquitin-dependent proteolysis is a highly complex,
temporally controlled, and acutely regulated enzymatic pro-
cess [16]. Regulation of certain proteins by the proteasome
machinery may be dependent on post-translational modi¢ca-
tions such as phosphorylation [21^24]. We and others have
previously demonstrated that p42/p44 MAP kinases phos-
phorylate HIF-1K/HIF-2K, in vitro and in vivo [17,25^27].
Hence, we attempted to investigate the possible role of the
p42/p44 MAP kinase cascade in HIF-1K degradation/stabili-
zation. In this study, we have demonstrated that either strong
and persistent activation of the p42/p44 MAP kinase pathway
or its inhibition with the MEK inhibitor, PD 98059, does not
signi¢cantly modify the induction/degradation pattern of
HIF-1K. These results correlate well with the previously dem-
onstrated data showing that the basal and growth factor-
stimulated activity of p42/p44 MAP kinases is not modi¢ed
by hypoxia in the cellular model we used [17]. Recently, Giac-
cia’s and Semenza’s groups have shown that PI-3kinase/
PTEN/Akt cascade regulates hypoxia- and growth factor-in-
duced HIF-1K stabilization in human glioblastoma-derived
cells and prostate cancer cells, respectively [28,29]. However,
in the cellular systems we use to induce HIF-1K in response to
a moderate or drastic hypoxic stress, the PI-3kinase/Akt path-
way is not activated (Berra, E. and Pouysse¤gur, J., unpub-
lished observations).
Alternatively, association with an ancillary protein may
control the targetting of some proteins through the protea-
some. A relevant example is the promoted instability of p53
by association with either papilloma virus E6 protein or
MDM2 [30^32]. p53/MDM2 form an autoregulatory feedback
loop, in which p53 can control its own levels by inducing the
expression of its negative regulator, MDM2. By analogy, we
hypothesized that the latter mechanism could also take place
in the case of HIF-1K. To test this hypothesis, we performed
the series of experiments summarized in this work. Taken
together, our ¢ndings greatly support an autoregulatory feed-
back loop controlled by the hypoxic stress. We ¢rst demon-
strate that the length of the hypoxic stress a¡ects HIF-1K
half-life upon reoxygenation. Second, we present evidence
that HIF-1K degradation is dependent on hypoxia-induced
transcription since actinomycin D is able to reduce the degra-
dation rate. Finally, and more speci¢cally, we demonstrate
that HIF-1-dependent transcription is required for the induc-
tion of a regulatory factor(s) targetting HIF-1K degradation.
Furthermore, the second isoform HIF-2K, which expression
like for HIF-1K is also controlled by O2 tension, appears to be
subjected to the same regulatory mechanism (data not shown).
Therefore, in keeping with the results presented here, we
would like to propose the model depicted in Fig. 5 for the
degradation of HIF-1K. In this model we propose that, under
normal pO2, HIF-1K is targetted to the proteasome by a
HPTF. According to this model, HPTF is a hypoxia-inducible
gene product which accumulates as a function of the length of
hypoxia, and therefore of HIF-1 activity. Along this work,
two proteins, pVHL and MDM2, have been suggested to
target the proteasomal degradation of HIF-1K [11,33]. If
some uncertainty remains for the case of MDM2, the role
of pVHL in the control of HIF-1K and HIF-2K has been
clearly established. It was therefore crucial to answer whether
HPTF is either pVHL or MDM2. pVHL was rapidly elimi-
nated, among these candidates, since hypoxia does regulate
neither the level of this protein nor its association with
HIF-1K (Fig. 4 and data not shown). As far as MDM2 is
concerned, it does not appear to be a hypoxia-regulated
gene although p53 tends to accumulate in response to severe
hypoxia [34]. Moreover, it has been reported that MDM2-
mediated p53 degradation requires nuclear export [35]. In-
deed, leptomycin B, known to prevent p53 degradation by
blocking nuclear export, does not a¡ect HIF-1K degradation
(Berra, E., Roux, D. and Pouysse¤gur, J., manuscript in prep-
aration). Furthermore, it is important to note that pVHL
associates constitutively with HIF-1K, even in hypoxic condi-
tions suggesting that there necessary exists a complementary
mechanism(s) modulating the oxygen-dependent pVHL-medi-
ated degradation of HIF-1K. We speculate that HPTF is
responsible for the conditional ‘switch’ of HIF-1K to O2-
mediated degradation. Upon return to an oxygenated en-
vironment, interaction of HPTF with the HIF-1K/pVHL
complex could ‘switch on’ the ubiquitination of HIF-1K en-
suring rapid degradation, and maintenance of low levels dur-
ing normoxia. We do not yet know the molecular nature of
HPTF nor the mechanisms regulating its interaction with the
HIF-1K/pVHL complex. Is there a direct interaction of HPTF
and HIF-1K or is this association mediated by pVHL? HIF-
2K is also subjected to the same regulatory mechanism, and
essentially identical results were obtained in every cellular sys-
tem tested (HeLa, HepG2, and 293) but how generalizable is
this model? Further research will help us to clarify these im-
portant questions.
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